<DOC>
	<DOCNO>NCT01755520</DOCNO>
	<brief_summary>The primary objective study ist test hypothesis ticagrelor superior Aspirin ( ASA ) fort prevention major cardio- cerebrovascular event ( MACCE ) patient undergo artery bypass operation . The primary efficiacy MACCE-endpoint composite cardiovascular death , myocardial infarction , recurent revascularisation , stroke twelve month coronary artery bypass operation .</brief_summary>
	<brief_title>Study Comparing Ticagrelor With Aspirin Prevention Vascular Events Patients Undergoing CABG</brief_title>
	<detailed_description>For stable patient underwent coronary bypass operation , Aspirin alone currently represent gold standard antiplatelet treatment . The CABG substudy PLATO-trial ( http : //www.nejm.org/doi/full/10.1056/NEJMoa0904327 ) comprising 1200 patient convincingly show high significant reduction cardiovascular all-cause mortality patient recieving Aspirin Ticagrelor compare subject randomize Aspirin plus Clopidogrel . Moreover result PLATO CABG substudy show benefit Ticagrelor increase decrease Aspirin dos . Therefore Ticagrelor monotherapy ( 2x 90mg/day ) appear offer best balance safety anticipate improved efficacy Aspirin ( 1x 100mg/day ) alone , data available support hypothesis . Hence study ( TiCAB ) assign pivotal efficacy safety study Ticagrelor patient undergo coronary artery bypass operation test hypothesis ticagrelor superior Aspirin prevention major cardio- cerebrovascular event ( MACCE ) patient population . The TiCAB trial design randomize , double-blind , double-dummy , parallel group , phase III , multicenter study , compare efficacy safety Ticagrelor 90mg administer twice daily Aspirin 100mg daily , prevention MACCE within first year CABG operation .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Patients 18 year age old 2 . Informed , write consent patient 3 . Indication CABG surgery : coronary three vessel disease , leave main stenosis , two vessel disease impair leave ventricular function ( &lt; 50 % ) 1 . Cardiogenic shock , haemodynamic instability 2 . Indication oral anticoagulation dual antiplatelet therapy stop CABG 3 . Need concomitant noncoronary surgery ( e.g . valve replacement ) 4 . Intolerance Allergy Ticagrelor ASA ingredients 5 . History bleed diathesis within three month prior presentation 6 . History significant gastrointestinal bleeding within six month prior presentation 7 . History intracranial hemorrhage 8 . History moderate severe liver impairment ( Child Pugh B C ) 9 . Chronic renal insufficiency require dialysis 10 . Patient increase risk bradycardic event ( e.g . patient without pacemaker sick sinus syndrome , 2nd 3rd degree AV block bradycardicrelated syncope ) 11 . Known , clinically important thrombocytopenia ( i.e . &lt; 100.000/Âµl ) 12 . Known , clinically important anaemia ( i.e . &lt; 10mg/dl ) 13 . Participation another investigational drug device study last 30 day 14 . Pregnancy lactation ( premenopausal woman 2 method reliable contraception , one must barrier method , require ) ; woman childbearing potential pregnancy test mandatory 15 . Concomitant oral intravenous therapy ( see example ) strong CYP3A inhibitor , CYP3A substrates narrow therapeutic index , strong CYP3A inducer stop course study Strong inhibitor : ketoconazole , itraconazole , voriconazole , telithromycin , clarithromycin , nefazadone , ritonavir , saquinavir , nelfinavir , indinavir , atazanavir , 1 litre daily grapefruit juice . Substrates narrow therapeutic index : cyclosporine , quinidine . Strong inducer : rifampin/rifampicin , phenytoin , carbamazepine . 16 . Life expectancy le 12 month may result protocol noncompliance risk lose followup , active cancer 17 . Indication major surgery ( e.g . cancer treatment , carotid surgery , cerebral surgery , major vascular surgery ) 18 . Previous enrollment randomization treatment present study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>CABG</keyword>
	<keyword>CAD</keyword>
	<keyword>antiplatelet drug</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Aspirin</keyword>
</DOC>